Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm
Acta Haematologica · 2025
DOI: 10.1159/000542286 ↗Kurz gefasst
Fallbericht in der Zeitschrift Acta Haematologica, 2025. Verfasst von Christina Klötzer und 13 weiteren Autor:innen. Beteiligte Einrichtung: University Leipzig Medical Center, Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, Leipzig, Germany. Hauptthemen laut MEDLINE: Anemia, Megaloblastic, Hearing Loss, Sensorineural, Thiamine, Myelodysplastic Syndromes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Thiamine-responsive megaloblastic anemia syndrome (TRMA) is a rare autosomal recessive disease with a homozygous or compound-heterozygous mutation in the SLC19A2 gene characterized by megaloblastic anemia, diabetes mellitus (DM), and sensorineural hearing loss with onset in childhood. Folic acid and vitamin B12 in serum are normal with dysplastic erythropoiesis in the bone marrow often mimicking myelodysplastic neoplasms (MDS) as a potential differential diagnosis. Thiamine substitution leads to normalization of anemia, without effects on hearing loss or DM. Case Presentation: We report about a 38-year-old male patient, presented with a 12-year history of anemia, insulin dependent DM, optic neuropathy, and a cataract since early childhood. The laboratory showed megaloblastic anemia. Other values were normal. The bone marrow smear showed dysplastic erythropoiesis with megaloblastic changes, and normal findings in cytogenetic and molecular genetic examinations. Next-generation sequencing-based diagnostics revealed a heterozygous missense variant in the SLC19A2 gene on the maternal allele and a 3.4 Mb inversion in the chromosomal region 1q24.2 with breaking points in FAM78B and SLC19A2 on the paternal allele. Treatment with oral thiamine 100 mg daily was initiated, and 12 weeks later hemoglobin levels and bone marrow morphology had normalized.
Conclusion
Late-onset TRMA should be considered in adult patients with indicative comorbidities and a typical phenotype, which may mimic features of MDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Leipzig Medical Center, Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, Leipzig, Germany.
- Comprehensive Cancer Center Central Germany, Leipzig, Germany.
- University Leipzig Medical Center, Institute of Human Genetics, Leipzig, Germany.
- Hematological Praxis Naunhof, Naunhof, Germany.
- University Leipzig Medical Center, Center for Rare Diseases, Leipzig, Germany.
Zitieren
APA
Klötzer, C., Schnabel, F., Kubasch, A. S., Jentzsch, M., Franke, G. N., Uhlig, J., Faust, H., Jauss, R. T., Oppermann, H., Popp, D., Metzeler, K. H., Lemke, J. R., Vučinić, V., & Platzbecker, U. (2025). Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm. Acta Haematologica. https://doi.org/10.1159/000542286
Vancouver
Klötzer C, Schnabel F, Kubasch AS, Jentzsch M, Franke GN, Uhlig J, et al. Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm. Acta Haematologica. 2025. doi:10.1159/000542286
BibTeX
@article{Kltzer2025,
author = {Klötzer, Christina and Schnabel, Franziska and Kubasch, Anne-Sophie and Jentzsch, Madlen and Franke, Georg-Nikolaus and Uhlig, Jens and Faust, Helene and Jauss, Robin-Tobias and Oppermann, Henry and Popp, Denny and Metzeler, Klaus H and Lemke, Johannes R and Vučinić, Vladan and Platzbecker, Uwe},
title = {Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm},
journal = {Acta Haematologica},
year = {2025},
doi = {10.1159/000542286}
}
EUVIMED